[1]葛 飞,孟凡亮.miR-146a/b在慢性阻塞性肺疾病患者血清中的表达及相关性分析[J].医学信息,2022,35(02):1-5.[doi:10.3969/j.issn.1006-1959.2022.02.001]
　GE Fei,MENG Fan-liang.Expression and Correlation Analysis of miR-146a/b in Serum of Patientswith Chronic Obstructive Pulmonary Disease[J].Medical Information,2022,35(02):1-5.[doi:10.3969/j.issn.1006-1959.2022.02.001]
点击复制

miR-146a/b在慢性阻塞性肺疾病患者血清中的表达及相关性分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年02期
页码:
1-5
栏目:
出版日期:
2022-01-15

文章信息/Info

Title:
Expression and Correlation Analysis of miR-146a/b in Serum of Patientswith Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2022）02-0001-05
作者:
葛 飞; 孟凡亮
安徽医科大学附属巢湖医院呼吸内科，安徽 合肥 238000
Author(s):
GE Fei; MENG Fan-liang
Department of Respiratory Medicine,Chaohu Hospital Affiliated to Anhui Medical University,Hefei 238000,Anhui,China
关键词:
慢性阻塞性肺疾病; 血清炎性标志物; miR-146a/b; 炎症反应; GOLD分期; 肺功能
Keywords:
Chronic obstructive pulmonary disease; Serum inflammatory markers; miR-146a/b; Inflammatory reaction; GOLD staging; Lung function
分类号:
R563.9
DOI:
10.3969/j.issn.1006-1959.2022.02.001
文献标志码:
A
摘要:
目的 探讨miR-146a和miR-146b在慢性阻塞性肺疾病患者血清中的表达情况，以及与血清炎性标志物、GOLD分期和肺功能指标的关系。方法 选取2020年1月-11月我院收治的急性加重期慢阻肺（AECOPD）患者90例，稳定期慢阻肺（stable COPD）患者90例，另选取年龄、性别与全部慢阻肺患者（AECOPD和stable COPD）相匹配的健康体检者（HCS）90例，分别设为急性加重期组、稳定期组及对照组。采用实时定量聚合酶链反应（Q-PCR）检测三组外周血清miR-146a和miR-146b的相对表达量，并检测超敏C反应蛋白（hs-CRP）、血沉（ESR）及降钙素原（PCT）的水平，1秒用力呼气量（FEV1）、FEV1预测值、1 秒用力呼气量/用力肺活量（FEV1/FVC），比较三组miR-146a和miR-146b的表达量及其与上述指标的相关性，分析其临床价值与意义。结果 急性加重期组血清中的miR-146a和miR-146b水平低于稳定期组和对照组（P＜0.05），但稳定期组和对照组比较，差异无统计学意义（P＞0.05）；急性加重期组PCT、CRP及ESR水平均高于稳定期组和对照组，且稳定期组高于对照组（P＜0.05）；急性加重期组FEV1、FEV1预测值、FEV1/FVC均低于稳定期组和对照组，且稳定期组低于对照组（P＜0.05）；急性加重期组各GOLD分级miR-146a/b表达量比较，差异有统计学意义（P＜0.05）；稳定期组各GOLD分级miR-146a/b表达量比较，差异有统计学意义（P＜0.05）；急性加重期组血清 miR-146a、miR-146b水平与PCT、CRP及ESR 均呈负相关（P＜0.05），与FEV1、FEV1预测值、FEV1/FVC均呈正相关（P＜0.05）；稳定期组血清miR-146a水平、miR-146b水平与PCT、CRP及ESR 均呈负相关（P＜0.05），与FEV1、FEV1预测值、FEV1/FVC均呈正相关（P＜0.05）。结论 miR-146a和miR-146b在慢阻肺急性加重期患者血清中低表达，与血清炎性标志物水平和GOLD分期呈负相关性关系，与肺功能指标呈正相关性关系，有望成为AECOPD诊断的重要生物分子标志物。
Abstract:
Objective To investigate the expression of miR-146 a and miR-146 b in serum of patients with chronic obstructive pulmonary disease, and its relationship with serum inflammatory markers, GOLD stage and lung function indexes.Methods A total of 90 patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and 90 patients with stable chronic obstructive pulmonary disease (stable COPD) in our hospital from January to November 2020 were selected, and 90 healthy subjects (HCS) matched with age and sex with all COPD patients (AECOPD and stable COPD), they were selected as acute exacerbation group, stable group and control group, respectively. Real-time quantitative polymerase chain reaction (Q-PCR) was used to detect the relative expression of miR-146 a and miR-146b in peripheral blood serum of the three groups, and the levels of high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR) and procalcitonin (PCT), forced expiratory volume in one second (FEV1), FEV1 predictive value, forced expiratory volume in one second/forced vital capacity (FEV1/FVC) were detected. The expression of miR-146 a and miR-146 b in the three groups and their correlation with the above indexes were compared, and their clinical value and significance were analyzed.Results The serum levels of miR-146a and miR-146b in the acute exacerbation group were lower than those in the stable group and control group (P<0.05); there was no significant difference between the stable group and control group (P>0.05). The levels of PCT, CRP and ESR in the acute exacerbation group were higher than those in the stable group and control group, and those in the stable group were higher than those in the control group (P<0.05). FEV1, FEV1 predictive value and FEV1/FVC in the acute exacerbation group were lower than those in the stable group and control group, and those in the stable group were lower than those in the control group (P<0.05). The expression levels of miR-146a/b in each GOLD classification in the acute exacerbation group were compared(P<0.05). The expression levels of miR-146a/b in each GOLD classification in the stable group were compared(P<0.05). The serum miR-146a and the serum miR-146b levellevel in the acute exacerbation group was negatively correlated with PCT, CRP and ESR (P<0.05), and positively correlated with FEV1, FEV1 predictive value and FEV1/FVC (P<0.05). The serum miR-146a level and the serum miR-146b level in the stable group was negatively correlated with PCT, CRP and ESR (P<0.05), and positively correlated with FEV1, FEV1 predictive value and FEV1/FVC (P<0.05).Conclusion miR-146a and miR-146b are lowly expressed in the serum of patients with acute exacerbation of chronic obstructive pulmonary disease, and are negatively correlated with the level of serum inflammatory markers and GOLD staging, and are positively correlated with lung function indexes. They are expected to become important biomarkers for the diagnosis of AECOPD.

参考文献/References:

[1]López-Campos JL,Tan W,Soriano JB.Global burden of COPD[J].Respirology,2016,21(1):14-23.[2]Goncalves PB,Romeiro NC.Multi-target natural products as alternatives against oxidative stress in Chronic Obstructive Pulmonary Disease (COPD)[J].European Journal of Medicinal Chemistry,2019(163):911-931.[3]Park H,Huang X,Lu C,et al.MicroRNA-146a and MicroRNA-146b Regulate Human Dendritic Cell Apoptosis and Cytokine Production by Targeting TRAF6 and IRAK1 Proteins[J].Journal of Biological Chemistry,2015,290(5):2831-2841.[4]Qiu Z,Li H,Wang J,et al.miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma[J].Oncology Reports,2017,38(5):2735-2740.[5]张凡,曹峰林,李俊儒,等.miR-146a在系统性红斑狼疮患者血清中表达及意义[J].中国优生与遗传杂志,2019,27(10):1163-1165,1247.[6]侯维纳,王芳洁,冯迎军.病毒性心肌炎患儿血清miR-1和miR-146b的表达水平及临床意义[J].热带医学杂志,2018,18(5):629-633.[7]朱丽娟,张振山,夏楠楠,等.老年原发性干燥综合征患者血清miR-146a和miR-155表达及临床意义[J].中国老年学杂志,2019,39(20):5020-5024.[8]蒲毅,冉思成.miR-146b、cTnI、CK-MB、IL-10和IL-21在病毒性心肌炎患者血清中的表达及意义[J].河北医药,2019,41(9):1373-1376.[9]Vij N,Chandramani-Shivalingappa P,Van Westphal C,et al.Cigarette smoke-induced autophagy impairment accelerates lung aging, COPD-emphysema exacerbations and pathogenesis[J].American Journal of Physiology Cell Physiology,2018,314(1):C73-C87.[10]Gong C,Yang Y,Chen M,et al.Effect of procalcitonin on the prognosis of patients with COPD[J]. Biomedical Reports,2020,12(6):313-318.[11]Sun X,Feng X,Zheng D,et al.Ergosterol attenuates cigarette smoke extract-induced COPD by modulating inflammation, oxidative stress and apoptosis in vitro and in vivo[J].Clinical Science,2019,133(13):1523-1536.[12]Sun G,Wang R,Li M,et al.Effect of a single nucleotide polymorphism in miR-146a on COX-2 protein expression and lung function in smokers with chronic obstructive pulmonary disease[J].International Journal of Chronic Obstructive Pulmonary Disease,2015(10):463-473.[13]Zhou S,Liu Y,Li M,et al.Combined Effects of PVT1 and MiR-146a Single Nucleotide Polymorphism on the Lung Function of Smokers with Chronic Obstructive Pulmonary Disease[J].International Journal of Biological Sciences,2018,14(10):1153-1162.[14]Zilahi E,Tarr T,Papp G,et al.Increased microRNA-146a/b, TRAF6 gene and decreased IRAK1 gene expressions in the peripheral mononuclear cells of patients with Sjogren’s syndrome[J].Immunology Letters,2012,141(2):165-168.[15]Wang J,Shang H,Yang X,et al.Procalcitonin, C-reactive protein, PaCO2, and noninvasive mechanical ventilation failure in chronic obstructive pulmonary disease exacerbation[J].Medicine,2019,98(17):e15171.[16]Mohamed A,Pekoz AY,Ross K,et al.Pulmonary delivery of Nanocomposite Microparticles (NCMPs) incorporating miR-146a for treatment of COPD[J].International Journal of Pharmaceutics,2019(569):118524.[17]Zheng C,Shu Y,Luo Y,et al.The role of miR-146a in modulating TRAF6-induced inflammation during lupus nephritis[J].European Review for Medical and Pharmacological Sciences,2017,21(5):1041-1048.[18]Meng Q,Liang C,Hua J,et al.A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance[J].Theranostics,2020,10(9):3967-3979.[19]Liu Y,Tsai M,Wu S,et al.miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway[J].Molecular Therapy Nucleic Acids,2020(22）:471-483.[20]Li Y,Zhang H,Dong Y,et al.MiR-146b-5p functions as a suppressor miRNA and prognosis predictor in non-small cell lung cancer[J].Journal of Cancer,2017,8(9):1704-1716.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Medical Information,2018,31(02):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(02):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Medical Information,2018,31(02):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(02):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Medical Information,2018,31(02):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
　ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(02):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
[10]张善芳,汤 杰.穴位注射联合沙美特罗替卡松粉吸入剂治疗 慢性阻塞性肺疾病稳定期的临床疗效观察[J].医学信息,2018,31(16):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
　ZHANG Shan-fang,TANG Jie.Clinical Observation of Acupoint Injection Combined with Salmeterol and Fluticasone Powder Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Medical Information,2018,31(02):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]

更新日期/Last Update: 1900-01-01